According to filings with the U.S. Securities and Exchange Commission, Apogee Therapeutics is raising $300,000,000.00 in new funding. About Apogee Therapeutics: Apogee Therapeutics is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and other inflammatory and immune (I&I) diseases with high unmet need. Apogee is seeking to reshape the current standard of care for inflammatory and immune diseases because we believe people living with these diseases deserve the best possible treatment. Our pipeline of differentiated antibody therapeutics targets well-established biological drivers and development pathways, with an initial focus on making impactful advancements in the treatment of atopic dermatitis and chronic obstructive pulmonary disease. Our seasoned team of skilled drug developers and operators are driven by the desire to give better treatment options to people living with inflammatory and immune diseases.

To learn more about Apogee Therapeutics, visit http://www.apogeetherapeutics.com/

Contact:
Michael Henderson, Chief Executive Officer
650-394-5230
https://www.linkedin.com/in/michael-henderson-387b6916/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.